Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 16/20 | 0.43 |
| ▸ | HTR2B | P41595 | 15/20 | 0.41 |
| ▸ | HTR2A | P28223 | 14/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6507759 | 0.70 | MAPT (0.41) | KDM4EALDH1A1CYP1A2 | |
| SCHEMBL6528522 | 0.67 | HTR2C (0.38) | HTR2CHTR2BHTR2A | |
| SCHEMBL3225974 | 0.64 | KDM4E (0.46) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL8911452 | 0.63 | DRD2 (0.56) | HTR2CHTR2BHTR2A | |
| SCHEMBL13119133 | 0.60 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL13119138 | 0.60 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL6630805 | 0.60 | PARP1 (0.43) | HTR2CKDM4EALDH1A1CYP1A2 | |
| Hydrochloric Acid SCHEMBL3559594 | 0.60 | HTR2C (0.98) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL3563962 | 0.60 | HTR2C (0.98) | HTR2CHTR2BHTR2A | |
| Hydrochloric Acid SCHEMBL6510200 | 0.59 | PARP1 (0.42) | HTR2CKDM4EALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032779-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2005-02-10 | — | — | US | disclosed |
| EP-1309594-B1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2004-12-15 | — | — | EP | disclosed |
| US-6794382-B2 | 6-OXO-5,6-DIHYDRO-4H-IMIDAZO(4,5,1-IJ)QUINOLINE DERIVATIVES AS INHIBITORS OF ADP-RIBOSYLTRANSFERASE; CARDIOVASCULAR, IMMUNOLOGICAL, RESPIRATORY SYSTEM, AND NEURODEGENERATIVE DISORDER TREATMENT | SANOFI-SYNTHELABO (FR) | 2004-09-21 | — | — | US | disclosed |
| US-20030203893-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2003-10-30 | — | — | US | disclosed |
| EP-1309594-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002012239-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-SYNTHELABO (FR) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032779-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | CBR3, CYP3A7, HDAC7 | HTR2C 466/4885HTR2B 1100/4885HTR2A 2017/4885 |
| US-20030203893-A1 | Benzimidazole derivatives, preparation and therapeutic use thereof | CBR3, HRH4, CBR1 | HTR2C 621/4885HTR2B 1337/4885HTR2A 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.